Literature DB >> 24935860

Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.

Claire N Harrison1, Nauman Butt, Peter Campbell, Eibhlin Conneally, Mark Drummond, Anthony R Green, Richard Murrin, Deepti H Radia, Adam Mead, John T Reilly, Nicholas C P Cross, Mary F McMullin.   

Abstract

Entities:  

Keywords:  calreticulin gene; myeloproliferative neoplasms; thrombocytosis

Mesh：

Year:  2014        PMID： 24935860     DOI： 10.1111/bjh.12986

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  13 in total

1.  Myeloproliferative neoplasms and personalized medicine: the perfect match?

Authors:  Jean-Jacques Kiladjian; Claire Harrison
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

Review 2.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

3.  Equivalence of BCSH and WHO diagnostic criteria for ET.

Authors:  C N Harrison; M F McMullin; A R Green; A J Mead
Journal:  Leukemia       Date:  2016-11-29       Impact factor: 11.528

4.  Essential Thrombocythemia among Patients with Myeloproliferative Neoplasms in Haematology Unit of a Tertiary Care Centre: A Descriptive Cross-sectional Study.

Authors:  Sanjit Kumar Sah; Sangam Shah; Sansar Babu Tiwari; Basanta Sharma Poudel; Biranmol Singh; Prakash Sharma; Sunil Sharma Acharya; Hritik Murarka; Sabin Thapaliya; Anjan Shrestha
Journal:  JNMA J Nepal Med Assoc       Date:  2022-04-15       Impact factor: 0.556

Review 5.  Clinical potential of pacritinib in the treatment of myelofibrosis.

Authors:  Ana B Duenas-Perez; Adam J Mead
Journal:  Ther Adv Hematol       Date:  2015-08

6.  Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Authors:  H Gisslinger; G Jeryczynski; B Gisslinger; A Wölfler; S Burgstaller; V Buxhofer-Ausch; M Schalling; M-T Krauth; A-I Schiefer; C Kornauth; I Simonitsch-Klupp; C Beham-Schmid; L Müllauer; J Thiele
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

7.  Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Authors:  Jacob Grinfeld; Jyoti Nangalia; E Joanna Baxter; David C Wedge; Nicos Angelopoulos; Robert Cantrill; Anna L Godfrey; Elli Papaemmanuil; Gunes Gundem; Cathy MacLean; Julia Cook; Laura O'Neil; Sarah O'Meara; Jon W Teague; Adam P Butler; Charlie E Massie; Nicholas Williams; Francesca L Nice; Christen L Andersen; Hans C Hasselbalch; Paola Guglielmelli; Mary F McMullin; Alessandro M Vannucchi; Claire N Harrison; Moritz Gerstung; Anthony R Green; Peter J Campbell
Journal:  N Engl J Med       Date:  2018-10-11       Impact factor: 91.245

Review 8.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

Review 9.  Guidelines for the management of myeloproliferative neoplasms.

Authors:  Chul Won Choi; Soo-Mee Bang; Seongsoo Jang; Chul Won Jung; Hee-Jin Kim; Ho Young Kim; Soo-Jeong Kim; Yeo-Kyeoung Kim; Jinny Park; Jong-Ho Won
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884

10.  MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.

Authors:  K Kollmann; J Nangalia; W Warsch; H Quentmeier; A Bench; E Boyd; M Scott; H G Drexler; A R Green
Journal:  Leukemia       Date:  2014-09-24       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.